TY - JOUR
T1 - From novel discovery tools and biomarkers to precision medicine-basic cardiovascular science highlights of 2021/22
AU - Evans, Paul C
AU - Davidson, Sean M
AU - Wojta, Johann
AU - Bäck, Magnus
AU - Bollini, Sveva
AU - Brittan, Mairi
AU - Catapano, Alberico L
AU - Chaudhry, Bill
AU - Cluitmans, Matthijs
AU - Gnecchi, Massimiliano
AU - Guzik, Tomasz J
AU - Hoefer, Imo
AU - Madonna, Rosalinda
AU - Monteiro, João P
AU - Morawietz, Henning
AU - Osto, Elena
AU - Padró, Teresa
AU - Sluimer, Judith C
AU - Tocchetti, Carlo Gabriele
AU - Van der Heiden, Kim
AU - Vilahur, Gemma
AU - Waltenberger, Johannes
AU - Weber, Christian
N1 - © The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
PY - 2022/10/21
Y1 - 2022/10/21
N2 - Here we review the highlights of cardiovascular basic science in published in 2021 and early 2022 on behalf of the European Society of Cardiology Council for Basic Cardiovascular Science. We begin with non-coding RNAs which have emerged as central regulators cardiovascular biology, and then discuss how technological developments in single-cell 'omics are providing new insights in cardiovascular development, inflammation and disease. We also review recent discoveries on the biology of extracellular vesicles in driving either protective or pathogenic responses. The Nobel Prize in Physiology or Medicine 2021 recognised the importance of the molecular basis of mechanosensing and here we review breakthroughs in cardiovascular sensing of mechanical force. We also summarise discoveries in the field of atherosclerosis including the role of clonal haematopoiesis of indeterminate potential, and new mechanisms of cross-talk between hyperglycemia, lipid mediators and inflammation. The past 12 months also witnessed major advances in the field of cardiac arrhythmia including new mechanisms of fibrillation. We also focus on inducible pluripotent stem cell (iPSC) technology which has demonstrated disease causality for several genetic polymorphisms in long QT syndrome and aortic valve disease, paving the way for personalized medicine approaches. Finally, the cardiovascular community has continued to better understand COVID-19 with significant advancement in our knowledge of cardiovascular tropism, molecular markers, the mechanism of vaccine-induced thrombotic complications and new anti-viral therapies that protect the cardiovascular system.
AB - Here we review the highlights of cardiovascular basic science in published in 2021 and early 2022 on behalf of the European Society of Cardiology Council for Basic Cardiovascular Science. We begin with non-coding RNAs which have emerged as central regulators cardiovascular biology, and then discuss how technological developments in single-cell 'omics are providing new insights in cardiovascular development, inflammation and disease. We also review recent discoveries on the biology of extracellular vesicles in driving either protective or pathogenic responses. The Nobel Prize in Physiology or Medicine 2021 recognised the importance of the molecular basis of mechanosensing and here we review breakthroughs in cardiovascular sensing of mechanical force. We also summarise discoveries in the field of atherosclerosis including the role of clonal haematopoiesis of indeterminate potential, and new mechanisms of cross-talk between hyperglycemia, lipid mediators and inflammation. The past 12 months also witnessed major advances in the field of cardiac arrhythmia including new mechanisms of fibrillation. We also focus on inducible pluripotent stem cell (iPSC) technology which has demonstrated disease causality for several genetic polymorphisms in long QT syndrome and aortic valve disease, paving the way for personalized medicine approaches. Finally, the cardiovascular community has continued to better understand COVID-19 with significant advancement in our knowledge of cardiovascular tropism, molecular markers, the mechanism of vaccine-induced thrombotic complications and new anti-viral therapies that protect the cardiovascular system.
U2 - 10.1093/cvr/cvac114
DO - 10.1093/cvr/cvac114
M3 - (Systematic) Review article
C2 - 35899362
SN - 0008-6363
VL - 118
SP - 2754
EP - 2767
JO - Cardiovascular Research
JF - Cardiovascular Research
IS - 13
ER -